Same mission. Same team. Stronger platform for life sciences, diagnostics, and combination drug product customers.
Carlsbad, CA — September 8, 2026 — Argonaut Manufacturing Services today announced that its life sciences, diagnostics, and combination drug product contract manufacturing business has transitioned to Aluris Sciences, a newly focused platform created to better serve the evolving needs of its customers and partners.
The transition to Aluris Sciences represents an important milestone in the company’s continued growth. While the name is changing, the mission remains the same: to provide reliable, high-quality, technically rigorous manufacturing solutions for customers developing life science tools, diagnostic platforms, and drug-device combination products.
Most importantly, customers will continue working with the same experienced team they know and trust.
“This is an exciting next step for our business, our employees, and our customers,” said Stacy Sutton, Chief Operating Officer. “Aluris Sciences reflects who we are today and where we are going — a focused, customer-first manufacturing partner built around quality, responsiveness, technical depth, and long-term partnership.”
The creation of Aluris Sciences is supported by 1315 Capital, a healthcare focused growth equity partner dedicated to the company’s continued success and, by extension, the success of its customers. This partnership provides Aluris Sciences with additional resources, strategic focus, and investment capacity to support continued expansion in quality systems, regulatory infrastructure, digital tools, technical capabilities, and manufacturing capacity.
For existing customers, the transition is designed to be seamless. Aluris Sciences will continue to operate with the same commitment to dependable supply, compliance, service, and manufacturing excellence that customers have come to expect.
The new structure creates a more focused operating model, enabling the business to make faster decisions, invest more directly in customer needs, and scale with the growing demands of development, clinical, validation, and commercial programs. The transition to a standalone platform strengthens the attributes customers value most when selecting and expanding contract manufacturing partnerships: supply reliability, uncompromising quality, technical expertise, speed, agility, and scalability.
“As Aluris Sciences, we are better positioned to invest in the capabilities that matter most to our customers,” added Billy Burris, Chief Commercial Officer. “This is not a change in who we are. It is an investment in what we can become for the partners who rely on us.”
Aluris Sciences will continue supporting customers across life sciences, diagnostics, and combination drug products with a focus on formulation, filling, kitting, lyophilization, assembly, packaging, supply chain solutions, and scalable manufacturing support from pilot-stage programs through commercialization.
For combination drug product customers specifically, Aluris Sciences will remain focused on the operational discipline, regulatory awareness, documentation rigor, and manufacturing reliability required to support complex drug-device and regulated healthcare programs. The company’s capabilities are aligned to help customers move from early technical transfer and process readiness through clinical, validation, and commercial manufacturing needs.
The company’s leadership team remains fully committed to maintaining operational continuity while building a stronger, more specialized platform for the future.
“Customers should expect continuity, clarity, and momentum,” said Burris. “Same mission. Same team. Same commitment to quality. Now with a sharper focus, stronger resources, and a platform built for long-term growth.”
KPMG Corporate Finance LLC acted as Argonaut Manufacturing Services’ exclusive financial advisor in this transaction.
About Aluris Sciences
Aluris Sciences is a focused contract manufacturing partner providing high-quality manufacturing solutions for life sciences, diagnostics, and combination drug product customers. With expertise across formulation, filling, kitting, lyophilization, assembly, packaging, supply chain management, and scalable manufacturing, Aluris Sciences supports customers from pilot-stage programs through clinical, validation, and commercial production. The company is headquartered in Carlsbad, California.
About 1315 Capital
1315 Capital is a private investment firm with over $1 billion of assets under management that provides growth capital to commercial-stage healthcare services, pharmaceutical & medtech outsourced services, pharmaceutical & medtech products, and health & wellness companies. 1315 Capital targets both minority and majority investments in companies where high-quality management teams can rapidly scale platform companies into large and important businesses that positively impact patients, physicians, and the broader healthcare system.
